In the News

Annovis Bio Completes Dose-Response Study of ANVS401 in Parkinson’s Disease

By September 1, 2021 No Comments

Annovis Bio Completes Dose-Response Study of ANVS401 in Parkinson’s Disease

Annovis Bio, Inc., has completed a two-part Phase 2a study of ANVS401 (also known as Posiphen), its investigational treatment for Alzheimer’s and Parkinson’s disease. ANVS401 works by inhibiting the formation of beta-amyloid and tau in Alzheimer’s and alpha-synuclein in Parkinson’s, which differs from other drugs that aim to clear these compounds after they’ve formed.

Part 1 of the Phase 2 studies showed that ANVS401 was effective in treating both Alzheimer’s and Parkinson’s. The safety and efficacy results of part 2, which studied a range of doses in 40 patients with Parkinson’s, will be released this fall. Annovis plans to complete its analysis of the data over the next few months before submitting it to the FDA in hopes of beginning a Phase 3 trial early next year.

Read more about ANVS401
CND Life Sciences

CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.